A carregar...

Relapse rates in patients with multiple sclerosis treated with fingolimod: subgroup analyses of pooled data from three phase 3 trials

BACKGROUND: Fingolimod is a once-daily, orally administered therapy for relapsing forms of MS. It has been shown to reduce relapse rates significantly in all phase II and phase III clinical trials when compared with placebo and intramuscular interferon β-1a (IFNβ-1a IM). METHODS: This study compared...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Mult Scler Relat Disord
Main Authors: Derfuss, Tobias, Ontaneda, Daniel, Nicholas, Jacqueline, Meng, Xiangyi, Hawker, Kathleen
Formato: Artigo
Idioma:Inglês
Publicado em: 2016
Assuntos:
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4985567/
https://ncbi.nlm.nih.gov/pubmed/27456887
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.msard.2016.05.015
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!